FDA Cites Pfizer Zyrtec-D Promotions For Lack Of Pseudoephedrine Risk Info
This article was originally published in The Tan Sheet
Executive Summary
Promotional materials for Pfizer's Zyrtec-D fail to discuss risks of the drug's decongestant component, an April 22 1FDA ad division letter says